Data completeness
1/8 — Limited
VAPO-ISO (isoproterenol hydrochloride) by Medica Corp is beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VAPO-ISO is an inhaled isoproterenol hydrochloride solution, a beta-adrenergic agonist with minimal alpha-adrenergic activity. It is a non-selective beta agonist delivered via inhalation for bronchospasm relief. This product is in pre-launch stage under NDA with Medica Corp as sponsor.
Pre-Launch
Early-stage asset with limited commercial footprint; team building and launch planning will drive near-term hiring.
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VAPO-ISO represents a pre-launch career opportunity with emphasis on regulatory clearance, market access, and launch infrastructure build. Career growth depends heavily on successful FDA approval and market adoption; early-stage entry offers visibility into all functional areas but carries execution risk.
Regulatory Affairs SpecialistBrand Manager
Worked on VAPO-ISO at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.